Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

CS-514

Known as: CS 514, CS514 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
BackgroundStatins are extensively used for cardiovascular disease prevention. Statins reduce mortality rates more than other… 
1990
1990
The preventive effects of simvastatin (MK-733) and pravastatin (CS-514), 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase… 
Highly Cited
1990
Highly Cited
1990
Nine patients with heterozygous familial hypercholesterolaemia were treated for eight weeks with either 40 mg pravastatin or… 
Highly Cited
1989
Highly Cited
1989
Pravastatin sodium (CS-514) is a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a key enzyme in… 
1989
1989
We examined the long-term effect of pravastatin, a new potent inhibitor of endogenous cholesterol biosynthesis, on glucose and… 
1988
1988
The hypolipidemic effect of a new HMG-CoA reductase inhibitor, pravastatin, was examined. The reductions of serum cholesterol and… 
Highly Cited
1987
Highly Cited
1987
CS-514 is a metabolic product of compactin and has a potent cholesterol-lowering effect in vitro and in animal studies by… 
1987
1987
Effects of CS-514, a new competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on serum lipoprotein lipid and… 
Highly Cited
1987
Highly Cited
1987
HMG-CoA reductase catalyzes the conversion of hydroxymethylglutarate to mevalonate, an important early rate-limiting step in the… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
1986
Highly Cited
1986
CS-514 is a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, a key enzyme in cholesterol synthesis…